-
Potential Treatment For Multiple Sclerosis Begins Clinical Trials
A potential treatment for multiple sclerosis (MS), developed by University of Greenwich in association with Kings College, London, has begun clinical trials.
The life sciences company BTG plc, which has licensed the research, is running the trials on a new compound, known as BGC20-0134.
Dr Laurence Harbige and Dr Mike Leach, from the Biomedical & ( Read more... ) -
Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
Peptimmune, Inc. a privately held biotechnology company, announced that it has completed its first clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of multiple sclerosis and other autoimmune diseases. The Phase I single ascending dose, double blind ( Read more... ) -
9/11 Tribute.
My 9-11 Tribute Page.
http://www.shof.msrcsites.co.uk/911.mp3
For the whole of today this page will be at the top of my blog - http://squiffy2.stumbleupon.com/ in commemoration of the many people, both civilians, Policemen and Firemen that lost their lives in the Twin Towers and other terrorist attacks on September 11th 2001.
May God Bless Them All.
-
Researchers uncover new pathway for popular Multiple Sclerosis drug
Researchers at UCSF and Stanford University have discovered a key mechanism responsible for the activity of a commonly prescribed drug for treating multiple sclerosis (MS), which they hope will spur better therapies for the disease.
The study was conducted on the drug glatiramer acetate (marketed as Copaxone), in mice with experimental autoimmune ( Read more... )